CSPC Pharmaceutical Group Launches Phase II Clinical Trial of SYH2070 Injection for Mixed Dyslipidemia, Targeting Enrollment of 240 Patients

Stock trading depends onJin Qilin Analyst Research ReportAuthoritative, professional, timely, and comprehensive—helping you uncover potential thematic opportunities!

(Source: National Business Daily)

NBD AI Flash: On July 7, CSPC Pharmaceutical Group Limited announced that the company had previously received the "Notice of Approval for Drug Clinical Trials" from the National Medical Products Administration and completed Phase I clinical trials. It is now announced that the Phase II clinical trial of its independently developed SYH2070 injection for the treatment of mixed hyperlipidemia has officially commenced at the first site in China. The trial plans to enroll 240 subjects, and recruitment and screening are currently progressing actively.